105 related articles for article (PubMed ID: 16814965)
1. Phenothiazine and carbazole-related compounds inhibit mitotic kinesin Eg5 and trigger apoptosis in transformed culture cells.
Okumura H; Nakazawa J; Tsuganezawa K; Usui T; Osada H; Matsumoto T; Tanaka A; Yokoyama S
Toxicol Lett; 2006 Sep; 166(1):44-52. PubMed ID: 16814965
[TBL] [Abstract][Full Text] [Related]
2. New chemical tools for investigating human mitotic kinesin Eg5.
Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L
Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586
[TBL] [Abstract][Full Text] [Related]
3. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.
DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F
Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of novel EG5 inhibitors.
Sarli V; Huemmer S; Sunder-Plassmann N; Mayer TU; Giannis A
Chembiochem; 2005 Nov; 6(11):2005-13. PubMed ID: 16216042
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors.
Takeuchi T; Oishi S; Watanabe T; Ohno H; Sawada J; Matsuno K; Asai A; Asada N; Kitaura K; Fujii N
J Med Chem; 2011 Jul; 54(13):4839-46. PubMed ID: 21599002
[TBL] [Abstract][Full Text] [Related]
6. Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.
Guido BC; Ramos LM; Nolasco DO; Nobrega CC; Andrade BY; Pic-Taylor A; Neto BA; Corrêa JR
BMC Cancer; 2015 Apr; 15():283. PubMed ID: 25885813
[TBL] [Abstract][Full Text] [Related]
7. A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
Ohira M; Iwasaki Y; Tanaka C; Kuroki M; Matsuo N; Kitamura T; Yukuhiro M; Morimoto H; Pang N; Liu B; Kiyono T; Amemiya M; Tanaka K; Yoshida K; Sugimoto N; Ohshima T; Fujita M
Biochim Biophys Acta; 2015 Sep; 1850(9):1676-84. PubMed ID: 25960391
[TBL] [Abstract][Full Text] [Related]
8. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
Shi J; Orth JD; Mitchison T
Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
[TBL] [Abstract][Full Text] [Related]
9. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
10. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
11. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
12. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.
Garcia-Saez I; DeBonis S; Lopez R; Trucco F; Rousseau B; Thuéry P; Kozielski F
J Biol Chem; 2007 Mar; 282(13):9740-9747. PubMed ID: 17251189
[TBL] [Abstract][Full Text] [Related]
13. CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity.
Jiang C; Yang L; Wu WT; Guo QL; You QD
J Pharm Pharmacol; 2011 Nov; 63(11):1462-9. PubMed ID: 21988427
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle-dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved antimitotic agents.
Birk M; Bürkle A; Pekari K; Maier T; Schmidt M
Int J Cancer; 2012 Feb; 130(4):798-807. PubMed ID: 21387302
[TBL] [Abstract][Full Text] [Related]
16. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
Peters T; Lindenmaier H; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):291-9. PubMed ID: 16365780
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors.
Holland JP; Kang A; Cohrs S; Selivanova SV; Milicevic Sephton S; Betzel T; Frey D; Wieser M; Jaussi R; Kammerer RA; Schibli R; Fischer E
Chem Biodivers; 2013 Apr; 10(4):538-55. PubMed ID: 23576341
[TBL] [Abstract][Full Text] [Related]
18. Induction of DNA fragmentation in human myelogenous leukaemic cell lines by phenothiazine-related compounds.
Sakagami H; Takahashi H; Yoshida H; Yamamura M; Fukuchi K; Gomi K; Motohashi N; Takeda M
Anticancer Res; 1995; 15(6B):2533-40. PubMed ID: 8669819
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
[TBL] [Abstract][Full Text] [Related]
20. Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment.
Marconi GD; Carradori S; Ricci A; Guglielmi P; Cataldi A; Zara S
Molecules; 2019 Oct; 24(21):. PubMed ID: 31683688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
